Prevalence of S and Z alpha 1-antitrypsin mutations in patients with pancreatic diseases in Serbian population by Nikolić Aleksandra et al.
 
____________________________  
Corresponding author: Aleksandra Divac, Institute of Molecular Genetics and 
Genetic Engineering, Vojvode Stepe 444a, PO Box 23,11010 Belgrade,Serbia,Tel: 
+381 11 3976658,Fax: +381 11 3975808,E-mail: aleksandradivac@imgge.bg.ac.rs 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
UDC 575:576.385 
                           DOI: 10.2298/GENSR1002377N 
Original scientific paper 
 
 
 
 
 
PREVALENCE OF S AND Z ALPHA 1-ANTITRYPSIN MUTATIONS IN 
PATIENTS WITH PANCREATIC DISEASES IN SERBIAN POPULATION 
 
Aleksandra NIKOLIC
1, Aleksandra DIVAC
1, Marija STANKOVIC
1, Jelena DINIC
1, 
Snezana LUKIC
2, Marina ANDJELIC-JELIC
3, Dragan POPOVIC
2,  
Dragica RADOJKOVIC
1 
 
1Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, 
Belgrade, Serbia 
2Department of Gastroenterology, Clinical Center of Serbia, Belgrade, Serbia 
3Department of Endocrinology, University Clinical Center “Zvezdara”, Belgrade 
 
Nikolić A., A. Divac, M. Stanković, J.Dinić, S.Lukić, M.Anđelić-Jelić, 
D.Popovuć,  and  D.Radojković  (2010):  Prevalence  of  s  and  z  alpha  1-
antitrypsin  mutations  in  patients  with  pancreatic  diseases  in  Serbian 
population.- Genetika, Vol 42, No. 2, 377-385. 
One  of the  key  points  in  research  of pancreatic  disease  pathology  is 
further elucidation  of  the role  of proteases and antiproteases, since their 
imbalance can lead to pancreatic injury. Alpha 1-antitrypsin (AAT) is one 
of the most important serum inhibitors of proteolytic enzymes, including 
pancreatic enzymes trypsin, chymotrypsin and elastase. It is speculated that 378                                                                                   GENETIKA, Vol. 42, No. 2, 377-385, 2010 
mutations in the AAT gene may influence the onset and the development of 
pancreatic disease. The presence of the most common AAT mutations Z 
and S was analyzed in 160 patients with pancreatic diseases (50 patients 
with pancreatic cancer, 50 patients with chronic pancreatitis and 60 patients 
with type 2 diabetes mellitus) and 129 healthy individuals by PCR-mediated 
site-directed  mutagenesis  (PSM)  method.  One  patient  with  pancreatic 
cancer was found to be a carrier of Z mutation, as well as one patient with 
type 2 diabetes mellitus. One patient with chronic pancreatitis was found to 
be a carrier of S mutation. The common AAT mutations were statistically 
significantly over-represented in patients with pancreatic diseases (3 of 160 
patients,  allelic  frequency  0.9%)  than  in  the  control  group  (1  of  129 
individuals,  allelic  frequency  0.4%).  The  results  of  this  study,  requiring 
confirmation,  suggest  that  common  AAT  mutations  Z  and  S  may  be 
associated with a modest increase in susceptibility to the development of 
pancreatic disease. 
Key words: alpha 1-anitripsin, pancreatic cancer, chronic pancreatitis, 
diabetes mellitus type 2, Z and S mutations 
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INTRODUCTION 
Pancreatic  cancer,  chronic  pancreatitis  and  type  2  diabetes  mellitus  are 
major  types  of  chronic  pancreatic  pathology,  but  their  etiology,  genetics  and 
underlying molecular mechanisms are still poorly understood (OTSUKI and TASHIRO 
2007;  WATANABE  et  al.  2007).  One  of  the  key  pathological  events  in  the 
development of pancreatic disease appears to be imbalance between proteases and 
their inhibitors within the pancreatic parenchyma (WEISS et al. 2008). It is known 
that mutations in the gene encoding cationic trypsinogen (PRSS1) play causative role 
in  the  hereditary  form  of  chronic  pancreatitis  (TEICH and  MÖSSNER  2008).  Other 
genes  encoding  proteases  and  their  inhibitors,  such  as  the  anionic  trypsinogen 
(PRSS2) and the serine protease inhibitor Kazal type 1 (SPINK1), have also been 
found to be associated with pancreatic disease. 
Alpha 1-antitrypsin (AAT) is the major serine protease inhibitor present in 
the blood (DEMEO and SILVERMAN 2004). Its main function is protection of lower 
respiratory tract tissue from proteolytic damage by neutrophil elastase, but it also 
inhibits a variety of proteases in other tissues, including trypsin, chymotrypsin and 
pancreatic elastase in the pancreatic parenchyma. The AAT protein is involved in 
processes  which  could  all  be  important  for  maintenance  of  normal  pancreatic 
function,  like  regulation  of  reactive  oxygen  species  toxicity,  cell-mediated 
immunity/tolerance,  neutrophil  and  endotoxin  mediated  inflammation,  endothelial 
function and apoptosis (SANDSTROM et al. 2008). The role of AAT is of particular 
interest in chronic pancreatitis, considering that pancreatitis is most likely caused by 
inappropriate  activation  of  pancreatic  zymogens  to  active  enzymes  within  the 
pancreatic parenchyma, leading to autodigestion and inflammation of the pancreas 
(TRUNINGER et al. 2001). The role of AAT also appears to be of importance in the A. DIVAC et al.: COMMON AAT MUTATION IN PANCREATIC DISEASES                              379 
development of pancreatic cancer, considering that AAT protein is overexpressed in 
malignant pancreatic tissue (TRACHTE et al. 2002). Recent finding that AAT protects 
endocrine pancreatic cells from apoptosis have pointed out that this molecule plays 
an important role not only in exocrine, but also endocrine pancreatic tissue (ZHANG 
et al. 2007). 
Gene encoding for AAT is highly polymorphic, with more than 120 allelic 
variants identified to date (DEMEO and SILVERMAN 2004; ZAIMIDOU et al. 2009). On 
the  basis  of  plasma  level  and  protein  function,  these  variants  are  categorized  as 
normal, deficient, null and dysfunctional. The most frequent AAT genetic variant is 
a glutamine to lysine substitution at codon 342 in exon 5 (E342K) giving rise to 
AAT protein variant PiZ (HUTCHISON 1998). The Z variant is both deficient and 
dysfunctional and in homozygous state can be the cause of severe AAT deficiency. 
The Z mutation gives only 15% of normal AAT serum levels in homozygotes and 
approximately  60%  in  heterozygotes  (CROWTHER  et  al.  2004).  Another  common 
AAT genetic variant is a glutamine to valine substitution at codon 264 in exon 3 
(E264V) giving rise to AAT protein variant PiS. The S variant is associated with 
increased risk of lung disease in combination with the Z variant (HUTCHISON 1998). 
Heterozygous  carriers  of  S  mutation  have  AAT  levels  80%  of  the  normal  AAT 
plasma levels; whereas homozygous carriers have AAT levels that are 60% of the 
normal AAT plasma levels (CROWTHER et al. 2004). The role of AAT deficiency is 
mostly investigated in lung disorders, such as lung emphysema, chronic obstructive 
pulmonary disease and lung cancer (DEMEO and SILVERMAN 2004; LJUJIC et al. 2006; 
YANG et al. 2008; TOPIC et al. 2010).  
Laboratory  diagnosis  of  AAT  deficiency  is  routinely  performed  by 
phenotyping  methods,  which  include  measurement  of  serum  alpha-1-antitrypsin 
concentration and isoelectric focusing (IEF). Several DNA-based methods are also 
used  for  AAT  deficiency  testing,  but  they  still  have  not  become  part  of  routine 
diagnostics (LJUJIC et al. 2008). There are a limited number of studies determining 
the frequency of common AAT variants by genotyping, especially for patients with 
pancreatic disease. To date, the role of AAT gene mutations in chronic pancreatitis 
remains unclear, while only few data are available regarding their potential role in 
pancreatic cancer and type 2 diabetes mellitus. The aim of this study was to estimate 
the prevalence of common AAT genetic variants, Z mutation and S mutation, in a 
series of Serbian subjects and to determine whether these mutations are associated 
with pancreatic diseases. 
 
MATERIALS AND METHODS 
This study has encompassed 160 patients with three major types of chronic 
pancreatic  pathology,  pancreatic  cancer,  chronic  pancreatitis  and  type  2  diabetes 
mellitus. The patients with pancreatic cancer and chronic pancreatitis were referred 
to the Clinic of Gastroenterohepatology and the First Surgical Clinic of the Institute 
for Digestive Diseases in the period 2004-2007. The patients with type 2 diabetes 
mellitus were referred to the Department of Endocrinology of the University Clinical 
Center “Zvezdara” in the period 2003-2006. 380                                                                                   GENETIKA, Vol. 42, No. 2, 377-385, 2010 
The group of patients with pancreatic cancer consisted of 50 individuals (30 
male and 20 female, 61.2±11.4  years). Diagnosis of pancreatic cancer was made 
based  on clinical findings  (abdominal  ultrasound,  computed  tomography,  nuclear 
magnetic  resonance  and  endoscopic  ultrasound)  and  laboratory  findings  (tumor 
marker CA 19-9 test). The diagnosis was confirmed by patohistological examination. 
The group of patients with chronic pancreatitis consisted of 50 individuals (42 male 
and 8 female, 52.0±12.4 years). Diagnosis of chronic pancreatitis was made based on 
the presence of exocrine and endocrine pancreatic insufficiency and the findings of 
morphological  examinations:  calcification  in  pancreas  detected  by  ultrasound, 
computed tomography or nuclear magnetic resonance of abdomen, morphological 
changes  of  the  pancreatic  canalicular  system  detected  by  endoscopic  retrograde 
cholangiopancreatography and morphological changes of the pancreas detected by 
endoscopic ultrasound. 
The  group  of  patients  with  type  2  diabetes  mellitus  consisted  of  60 
individuals  (20  male  and  40  female,  59.1±10.0  years)  in  whom  diabetes  was 
diagnosed  using  glucose  cut-off  values  as  defined  by  the  WHO.  Microvascular 
complications  of  diabetes,  polyneuropathy  and  retinopathy,  were  diagnosed  by 
neurological examination (clinical examination, EMNG, monofilament testing and 
Neuro-pad testing) and FOU examination. 
Control  group  consisted  of  129  healthy  blood  donors  (93  male  and  36 
female,  40.1±10.5  years)  who  were  referred  to  the  National  Blood  Transfusion 
Institute in the period 2000-2002. They were included in the study based on standard 
blood analyses, blood pressure measurement and absence of chronic diseases. 
Genomic DNA was extracted from peripheral blood using GFX
TM Genomic 
Blood DNA Purification  Kit (Amersham Biosciences). The presence  of the  most 
common mutated AAT alleles, Z and S, was detected by PCR-mediated site-directed 
mutagenesis (PSM) method (DIVAC et al. 2004). Fragments containing Z and S 
mutations were coamplified in the same reaction. Primers used for detection of Z 
mutation  were  GCCGTGCATAAGGCTGTGCTGACCATCGT*C  and 
TTGAGGAGCGAGAGGCAGTT.  Primers  used  for  the  detection  of  S  mutation 
were  CCTGATGAGGGGAAACTACAGCACCTC*G  and 
CAGTCCCAACATGGCTAAGAGGTG.  Both  forward  primers  introduce  the 
recognition site for the same restriction enzyme, TaqI. The amplification was carried 
out in a 25µL mixture containing 1x reaction buffer (50mM KCl, 10mM Tris-HCl 
(pH 9), 0.1% Triton X-100), 2.5mM MgCl2, 0.2mM of each dNTP, 5pmol of each 
primer, 1U of Taq polymerase (Promega) and 100-200ng of DNA. The amplification 
conditions were as follows: initial denaturation at 94°C for 5 minutes, 35 cycles of 
30 second denaturation at 94°C, 30 second annealing at 60°C, 30 second extension at 
72°C, with final extension of 10 minutes at 72°C. The obtained PCR product was 
digested with TaqI restriction enzyme (New England BioLabs) for 3h at 65°C. The 
digestion products were subjected to electrophoresis in 3% agarose gel in 1xTAE 
buffer at 100V for 2h. The bands were visualized by ethidium bromide staining. The 
normal alleles are cut with TaqI, giving raise to fragments of 181bp and 29bp for Z 
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Differences in allele and genotype frequencies between the analyzed groups 
were tested by SPSS software (version 10.0.1 for Windows) using Fisher’s exact 
test. The obtained p-values were adjusted for age and sex using logistic regression 
analysis, with p≤0.05 considered statistically significant. 
Written  informed  consent  was  obtained  from  all  study  participants  and  the 
investigation was approved by the hospital’s ethical committee. 
 
RESULTS 
To our knowledge, this is the first study analyzing the presence of the most 
common AAT variants by genotyping in patients with pancreatic cancer and type 2 
diabetes mellitus. Only one previous study reported on AAT genotyping in chronic 
pancreatitis patients (WITT et al. 2002). 
The results of genotyping performed in 160 patients with pancreatic disease 
and 129 controls are given in Table 1. The presence of Z and S mutations in the AAT 
gene was detected in 3 of 160 patients (allelic frequency 0.9%), while in control 
group 1 of 129 individuals was a mutation carrier (allelic frequency 0.4%). Statistical 
analysis  showed  no  significant  differences  between  the  patients  groups  and  the 
control group. However, statistically significant over-representation of the AAT S 
and Z mutations was found in all pancreatic disease cases combined in comparison 
to the control group (p=0.044).  
 
Table 1. Distribution of mutated AAT alleles in patients and in control group 
  chromosomes 
analyzed 
S 
allele 
Z 
allele 
mutated chromosomes 
(allelic frequency) 
pancreatic disease  320  1  2  3  (0.9%) 
pancreatic cancer  100  0  1  1  (1.0%) 
chronic pancreatitis  100  1  0  1  (1.0%) 
type 2 diabetes mellitus  120  0  1  1  (0.8%) 
control group  258  0  1  1  (0.4%) 
. 
In our study, the prevalence of common AAT variants in group of patients 
with pancreatic cancer showed no difference from the control group. So far, there 
have been  no data regarding the prevalence of deficient AAT variants in patients 
with pancreatic carcinoma using genotyping. The concentration of AAT was found 
to be elevated in plasma of pancreatic cancer patients, but no difference was found in 
phenotype  distribution among patients and controls (TOUNTAS et  al. 1985). AAT 
protein is overexpressed in malignant pancreatic tissue (TRACHTE et al. 2002). The 
elevated  levels  of  AAT  in  pancreatic  cancer  could  be  the  consequence  of  the 382                                                                                   GENETIKA, Vol. 42, No. 2, 377-385, 2010 
inflammatory  response  observed  to  be  associated  with  malignancies  or  it  could 
represent a protective mechanism against the proteases produced by the malignant 
cells. The AAT deficiency could lead to the uncontrolled degradation of pancreatic 
tissue  as  a  result  of  protease-antiprotease  imbalance  and  to  an  increased 
inflammatory response. 
The speculation of AAT involvement in chronic pancreatitis was prompted 
by several studies (EDMUNDS and  WILKINSON 1991;  RABASSA et al. 1995). Since 
AAT acts as a protease inhibitor, it could be important in prevention of pancreatic 
tissue autodigestion. Increased AAT concentration was found in pancreatic juice of 
patients with chronic pancreatitis (MISZCZUK-JAMSKA et al. 1983). It was speculated 
that  this  could  alter  the  balance  in  pancreatic  protease-antiprotease  system  and 
subsequently  lead  to  chronic  pancreatitis.  Only  one  study,  beside  this  one,  used 
genotyping to determine the frequency of Z and S mutations in chronic pancreatitis 
patients (WITT et al. 2002). In both studies no statistical difference was found in 
distribution of Z and S mutations between patients and controls. When the studies 
using measurement of AAT concentration and phenotyping are taken into account, 
the conflicting data  are obtained regarding the involvement of the AAT variants in 
chronic pancreatitis. Some findings indicated increased prevalence of PiS and PiZ in 
chronic alcoholic patients, while others indicated no difference (BRAXEL et al. 1982; 
EDMUNDS and WILKINSON 1991; RABASSA et al. 1995). 
The idea about AAT involvement in type 2 diabetes mellitus was raised by 
several functional studies, which showed that AAT prevents both diabetes formation 
in non-obese diabetic mice and B-cell apoptosis in vitro (LU et al. 2006; ZHANG et al. 
2007). To our knowledge, this is the first study investigating association of AAT gene 
variants with type 2 diabetes mellitus using genotyping. Recently, the frequency of 
AAT deficient variants, determined by IEF phenotyping, was shown to be increased 
in patients with type 2 diabetes mellitus compared to non-diabetic control subjects 
(SANDSTROM  et  al. 2008).  Also, the  number  of individuals with low  AAT  levels 
(<1.0 mg/ml) was 50% higher in the diabetic group (p<0.05). Several other studies 
showed  abnormal  AAT  levels  in  patients  with  type  1  diabetes  mellitus,  but  no 
phenotyping  or  genotyping  for  these  patients  was  done  (SANDLER  et  al.  1988; 
LISOWSKA-MYJAK et al. 2006). In our study, the increase in frequency of mutated 
alleles in type 2 diabetes mellitus patients compared to the control group was not 
statistically  significant.  The  reason  for  this  could  be  a  small  number  of  patients 
involved in the study. 
Our  study  showed  that  there  is  a  statistically  significant  increase  in  the 
frequency  of  the  tested  mutated  alleles  in  patients  with  pancreatic  diseases  in 
comparison to the control group, which could indicate importance of the AAT gene 
for  the  pathogenesis  of  pancreatic diseases.  Confirmation of  the  results in  larger 
cohort  of  the  patients  and  in  different  populations  is  needed.  It  would  be  also 
beneficial to screen the whole AAT gene, considering the number of identified AAT 
variants (DEMEO and SILVERMAN 2004, LJUJIC et al. 2006). The results of this study 
suggest that common AAT mutations Z and S may be associated with a modest 
increase in susceptibility to the development of pancreatic disease. A. DIVAC et al.: COMMON AAT MUTATION IN PANCREATIC DISEASES                              383 
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I z v o d 
 
Jedan od osnovnih izazova u proučavanju patologije bolesti pankreasa predstavlja 
dalje  razjašnjavanje  uloge  proteaza  i  antiproteaza,  zbog  toga  što  poremećena 
ravnoteža  između  njih  može  dovesti  do  oštećenja  pankreasa.  Alfa  1-antitripsin 
(AAT)  je  jedan  od  najvažnijih  inhibitora  proteolitičkih  enzima  u  serumu,  među 
kojima  su  i  enzimi  pankreasa:  tripsin,  himotripsin  i  elastaza.  Pretpostavlja  se  da 
mutacije u AAT genu mogu da utiču na pojavu i razvoj bolesti pankreasa. Prisustvo 
najčešćih mutacija u AAT genu, označenih kao Z i S, analizirano je u 160 pacijenata 
sa  bolestima  pankreasa  (50  pacijenata  sa  kancerom  pankreasa,  50  pacijenata  sa 
hroničnim pankreatitisom i  60  pacijenata  sa dijabetesom  tipa  2)  i  u  129 zdravih 
osoba. Prisustvo mutacija detektovano je analizom dužina restrikcionih fragmenata. 
Jedan pacijent sa kancerom pankreasa je bio heterozigotni nosilac Z mutacije, kao i 
jedan pacijent sa dijabetesom tipa 2. Jedan pacijent sa hroničnim pankreatitisom je 
bio  heterozigotni  nosilac  S mutacije.  Dve  najčešće  mutacije  u  AAT  genu  su  bile 
statistički  značajno  učestalije  kod  pacijenata  sa  bolestima  pankreasa  (3  /  160 
pacijenata, alelska frekvencija 0,9%) nego u kontrolnoj grupi (1 / 129 osoba, alelska 
frekvencija 0,4%). Rezultati ove studije, koje ukazuju na moguću povezanost Z i S 
mutacija sa umerenim povećanjem rizika za razvoj bolesti pankreasa. 
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